Patients with advanced pancreatic cancer and their families may be asking whether daraxonrasib offers another treatment option after chemotherapy. The medicine, developed by Revolution Medicines and marketed as RASONQUE, is an oral drug designed to target active RAS proteins. The FDA approved it on August 26, 2026, for adults with previously treated metastatic pancreatic ductal adenocarcinoma.
Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, and RAS mutations occur in more than 90% of these tumors. Daraxonrasib is a RAS(ON) multiselective tri-complex inhibitor. It binds cyclophilin A to block active, GTP-bound RAS signaling. In the Phase 3 RASolute 302 trial, which included 500 patients, median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy. Median progression-free survival was 7.2 months and 3.6 months, respectively.
For patients, the practical question is whether the approved treatment fits their situation. The FDA approval covers adults with previously treated metastatic pancreatic ductal adenocarcinoma. Patients should discuss treatment decisions and eligibility with their oncology team; tumor testing and individual clinical findings may inform care.
The drug’s mechanism is intended to address multiple active RAS mutations, including mutations such as G12D and G12V. In the trial’s RAS G12 population, which accounted for 91.8% of participants, median overall survival was 13.2 months with daraxonrasib and 6.6 months with chemotherapy. Median progression-free survival was 7.3 months and 3.5 months, respectively.
Is daraxonrasib effective for all pancreatic cancer patients?
No. Trial results do not show that it works for every patient. The drug is approved for a defined group of adults with previously treated metastatic pancreatic ductal adenocarcinoma. Response and risks depend on individual clinical findings. It should not be described as a cure or a replacement for every standard treatment.
The FDA also granted breakthrough therapy designation in September 2026 to daraxonrasib combined with gemcitabine and nab-paclitaxel as a first-line treatment for metastatic pancreatic cancer. The Phase 3 RASolute 303 trial of that combination is ongoing.